

2017-2018

American Heart Association

Support from Pharmaceutical and Biotech Companies, Device Manufacturers and Health Insurance Providers

We value the trust placed in us by our donors, supporters and the general public, and we feel the best way to continue to earn that trust is to make the association's finances as transparent as possible. In fact, the American Heart Association has consistently met the high standards of the [Better Business Bureau's Wise Giving Alliance \(WGA\)](#), the premier organization evaluating charitable organizations.


Most of the revenue recorded by the American Heart Association comes from sources other than corporations. These sources include contributions from individuals, foundations and estates as well as investment earnings and revenue from the sale of educational materials.

Financial support from corporations helps the association's programs and campaigns more effectively achieve our goals of improving the cardiovascular health of all Americans and saving more lives. All corporate relationships are required to comply with the association's corporate relations policies, and regional and national corporate relationships are approved by a committee of national volunteers and executive staff.

Total corporate support is comprised of unrestricted gifts and special event and program sponsorships, and includes support committed to the American Heart Association at the national, regional and local levels. Corporate Support represents approximately 19.3 percent of the AHA's \$933 million total revenue.

Support that the American Heart Association receives from pharmaceutical and biotech companies, device manufacturers and health insurance providers is included within total corporate support and represents approximately 3.6 percent of the association's total revenue. The majority of funding from these sources occurs at the national level.

The revenue figures below include the total amount of funds committed to the American Heart Association during fiscal year 2017-2018, noting that, in some cases, the funds will be received in future years. The chart provides funds committed from pharmaceutical and biotech companies, device manufacturers and health insurance providers in proportion to all sources of revenue.



Listed below in the middle column is cash received by the American Heart Association from pharmaceutical and biotech companies, device manufacturers and health insurance providers during fiscal year 2017-2018.

In addition, the right column reflects revenue that was committed to the American Heart Association during fiscal year 2017-2018 but will be received in future years. An example is a multi-year sponsorship of an American Heart Association program or campaign.

2017-2018 Corporate Support Received From Pharmaceutical and Biotech Companies, Medical Device Manufacturers and Health Insurance Providers		
Corporation	Total Cash Received During FY 2017-2018 on Prior and Current Year Commitments (1)	FY 2017-2018 Commitments Receivable in the Future
3M	195,000	225,000
Abbott	18,150	-
Aegerion	10,000	-
Amarin	255,000	190,000
Amerihealth Caritas Keystone First	125,000	-
AmerisourceBergen	150,000	-
Amgen	888,750	974,800
Amgen/Ascend	-	40,000
Anthem	1,856,487	-
Aralez Pharmaceuticals	405,000	-
AstraZeneca	973,221	903,365
Bayer Crop Science	400,000	-
Bayer Healthcare	1,171,500	1,070,000
Blue Shield of California	250,000	500,000
BMS/Pfizer	442,055	640,000
BMS Foundation	789,600	-
BI/Lilly	-	5,000,000
Boehringer Ingelheim Pharmaceuticals	1,021,750	625,000
Carefirst BlueCross BlueShield	168,750	-
Cerenovus	10,000	-
Chiesi	15,000	10,000
Denka Seiken USA	10,000	-
Edwards Lifesciences LLC	550,000	-
Florida Blue	-	150,000
Gilead Sciences	84,775	-
Ionis	2,000	-
Independence Blue Cross	1,000	375,000
Jabil	-	225,000
Janssen	955,500	133,335
Kaiser Permanente	50,000	450,000
Laerdal Medical Corporation	600,000	-
Medtronic/Covidien/EV3	2,904,000	317,000
Merck	105,000	-
MyoKardia	25,000	-
Nephron Pharmaceuticals	150,000	-
NICO	25,000	-
Novartis Pharmaceuticals	3,871,000	5,240,809
NovoNordisk	412,500	5,000,000
Pfizer	1,257,907	549,595
Philips Healthcare	275,000	-
Physio-Control	20,000	-
Premera Blue Cross	350,000	-
Sanofi	1,007,500	37,500
SciEx	1,500	-
Stryker Neurovascular	4,107,122	-
Transamerica	535,000	-
Verily (Google Life Science)	1,884,817	-
Western Health Advantage	-	345,000
WorldPoint	10,000	20,000
Zoll Medical	15,000	-
Totals	28,354,884	23,021,404

NOTE: (1) Reflects all cash received from corporate contributions to National Center and ten highest corporate contributions to each Affiliate. Revenue related to the cash receipts was recorded within AHA's financial statements over the periods from fiscal year 2014-15 through fiscal year 2017-18.